Ikarian Capital, LLC Rigel Pharmaceuticals Inc Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.67 - $3.19 $961,017 - $4.58 Million	-1,434,355 Reduced 67.12%	702,773 $794,000
Q1 2022 May 13, 2022	BUY	$2.22 - $3.45 $3.77 Million - $5.86 Million	1,697,772 Added 386.42%	2,137,128 $6.39 Million
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $1.04 Million - $1.57 Million	439,356 New	439,356 $1.16 Million
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $1.16 Million - $1.7 Million	-345,529 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$2.35 - $3.74 $822,500 - $1.31 Million	-350,000 Reduced 50.32%	345,529 $1.21 Million
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $1.75 Million - $4.07 Million	-985,000 Reduced 58.61%	695,529 $1.67 Million
Q1 2020 May 15, 2020	BUY	$1.27 - $3.0 $1.69 Million - $3.99 Million	1,330,529 Added 380.15%	1,680,529 $2.62 Million
Q4 2019 Jan 31, 2020	BUY	$1.6 - $2.43 $560,000 - $850,500	350,000 New	350,000 $749,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.